Shanghai Henlius Biotech (HKG:2696) dosed the first patient in the third stage of a phase 2/3 clinical trial of Hansizhuang in combination with bevacizumab injection and chemotherapy in Japan, a Thursday bourse filing said.
The drug is indicated for the first-line treatment of metastatic colorectal cancer.
A phase 3 study of the drug is also ongoing in mainland China and Indonesia.
Price (HKD): $21.70, Change: $-0.20, Percent Change: -0.91%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。